Advertisement

American Journal of Clinical Dermatology

, Volume 5, Issue 3, pp 189–197 | Cite as

Eosinophilic Pustular Folliculitis

A Comprehensive Review of Treatment Options
  • Elliot Ellis
  • Noah Scheinfeld
Review Article

Abstract

Eosinophilic pustular folliculitis (EPF), also known as Ofuji disease, is a disease that manifests with follicular papules or pustules. Its variants include a classic type that occurs most commonly in Japan, an HIV-associated type, an infantile type, a type that occurs on the palms and soles, a rare medication-associated variant, and a rare neoplasia-associated variant.

A wide range of medications has been used to treat EPF. Topical corticosteroids are the first-line treatment option for EPF. Topical tacrolimus seems to be useful initial therapy as well. Oral indometacin (50–75 mg/day) is an effective treatment of classic EPF although it can induce peptic ulcers. For treatment of HIV-associated EPF when topical corticosteroids and indometacin do not work, various other treatments should be considered. These treatment options include cetirizine 20–40 mg/day, metronidazole 250mg three times a day, itraconazole starting at a dosage of 200 mg/day and increasing to 300–400 mg/day, and topical permethrin. If these treatments do not work phototherapy with UVB is the ‘gold standard’ of treatment and is often curative. Treatments with less certain risk-benefit ratios but with some efficacy include PUVA (psoralen + UVA) photochemotherapy, oral corticosteroids, synthetic retinoids (i.e. isotretinoin 1 mg/kg/day), and acitretin (0.5 mg/kg/day), oral cyclosporine (ciclosporine) 5 mg/kg/day, interferon (IFN)-α-2b, and IFNγ. Minocycline 100mg twice daily and dapsone 50–100mg twice daily have been used with some effect. The use of highly active antiretroviral therapy for HIV has resulted in the amelioration of EPF as CD4 cell counts rise above 250/mm3. The diversity of clinical presentations and affected populations make it seem that EPF is a reaction pattern as much as a disease and that therapy should be tailored to the variant of EPF and the underlying etiology.

Keywords

Itraconazole Isotretinoin Topical Corticosteroid Dapsone Cetirizine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Ise S, Ofuji S. Subcorneal pustular dermatosis: a follicular variant? Arch Dermatol 1965; 92: 169–71CrossRefGoogle Scholar
  2. 2.
    Ofuji S, Ogino A, Horio T, et al. Eosinophilic pustular folliculitis. Acta Derm Venereol 1970; 50: 195–203PubMedGoogle Scholar
  3. 3.
    Johnson RA. Cutaneous manifestations of human immunodeficiency virus disease. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2003: 2138–50Google Scholar
  4. 4.
    Weedon D. Diseases of cutaneous appendages. In: Weedon D, editor. Skin pathology. London: Churchill Livingstone, 2002Google Scholar
  5. 5.
    Soeprono FF, Schinella RA. Eosinophilic pustular folliculitis in patients with acquiredimmune deficiency syndrome. J Am Acad Dermatol 1986; 14: 1020–2PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenthal D, Leboit PE, Klumpp L, et al. Human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol 1991; 127: 206–9PubMedCrossRefGoogle Scholar
  7. 7.
    Lucky AW, Esterly NB, Heskel N, et al. Eosinophilic pustular folliculitis in infancy. Pediatr Dermatol 1984; 1: 202–6PubMedCrossRefGoogle Scholar
  8. 8.
    Patrizi A, Di Lernia V, Neri I, et al. Eosinophilic pustular folliculitis (Ofuji’s disease) and non-Hodgkin lymphoma. Acta Derm Venereol 1992; 72: 146–7PubMedGoogle Scholar
  9. 9.
    Lambert J, Berneman Z, Dockx P, et al. Eosinophilic pustular folliculitis and B-cell chronic lymphatic leukaemia. Dermatology 1994; 189 Suppl. 2: 58–9PubMedCrossRefGoogle Scholar
  10. 10.
    Roger H, Souteyrand P, Bignon YJ, et al. Eosinophilic pustular folliculitis disclosing high-grade rapidly fatal T lymphoma. Ann Dermatol Venereol 1988; 115: 1209–12PubMedGoogle Scholar
  11. 11.
    Kishimoto S, Yamamoto M, Nomiyama T, et al. Eosinophilic pustular folliculitis in association with nevoid basal cell carcinoma syndrome. Acta Derm Venereol 2001; 8: 202–4Google Scholar
  12. 12.
    Takematsu H, Nakamura K, Igarashi M, et al. Eosinophilc pustular folliculitis: reports of two cases with a review of the Japanese literature. Arch Dermatol 1985; 121: 917–20PubMedCrossRefGoogle Scholar
  13. 13.
    Magro CM, Crowson AN. Eosinophilic pustular follicular reaction: a paradigm of immune dysregulation. Int J Dermatol 1994; 33: 172–8PubMedGoogle Scholar
  14. 14.
    Boone M, Dangoisse C, Andre J, et al. Eosinophilic pustular folliculitis in three atopic children with hypersensitivity to Dermatophagoides pteronyssinus. Dermatology 1995; 190: 164–8PubMedCrossRefGoogle Scholar
  15. 15.
    Kimura K, Ezoe K, Yokozeki H, et al. A case of eosinophilic pustular folliculitis (Ofuji’s disease) induced by patch and challenge tests with indeloxazine hydrochloride. J Dermatol 1996; 23: 479–83PubMedGoogle Scholar
  16. 16.
    Giard F, Marcoux D, McCuaig C, et al. Eosinophilic pustular folliculitis (Ofuji disease) in childhood: a review of four cases. Pediatr Dermatol 1991; 8: 189–93PubMedCrossRefGoogle Scholar
  17. 17.
    Dyall-Smith D, Mason G. Fungal eosinophilic pustular folliculitis. Australas J Dermatol 1995; 36: 37–8PubMedCrossRefGoogle Scholar
  18. 18.
    Bachmeyer C, Cordier F, Cazier A, et al. Eosinophilic folliculitis associated with AIDS after antiretroviral tri-therapy [letter]. Presse Med 1999; 28: 2226Google Scholar
  19. 19.
    Mizoguchi S, Setoyama M, Higashi Y, et al. Eosinophilic pustular folliculitis induced by carbamazepine. J Am Acad Dermatol 1998; 38: 641–3PubMedCrossRefGoogle Scholar
  20. 20.
    Maejima H, Mukai H, Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. Acta Derm Venereol 2002; 82: 316–7PubMedCrossRefGoogle Scholar
  21. 21.
    Odom RB, James WD, Berger TG. Andrews’ diseases of the skin: clinical dermatology. Philadelphia (PA): WB Saunders Company, 2000Google Scholar
  22. 22.
    Sano S, Itami S, Azukizawa H, et al. Interleukin 5-inducing activity in the blister fluid of eosinophilic pustular dermatosis. Br J Dermatol 1999; 141: 154–5PubMedCrossRefGoogle Scholar
  23. 23.
    Grange F, Schoenlaub P, Tortel MC, et al. AIDS-related eosinophilic folliculitis: efficacy of high dose topical corticotherapy. Ann Dermatol Venereol 1996; 123: 456–9PubMedGoogle Scholar
  24. 24.
    De Dulanto F, Armijo Moreno M, Diaz Flores L, et al. Eosinophilic pustular folliculitis (Ofuji syndrome). Med Cutan Ibero Lat Am 1977; 5: 323–9PubMedGoogle Scholar
  25. 25.
    Hosokawa H, Asada Y. A case of eosinophilic pustular folliculitis successfully treated with indomethacin. Hifu 1984; 26: 560–2Google Scholar
  26. 26.
    Miyauchi T, Fujigaki T, Uehara M, et al. Successful treatment of eosinophilic pustular folliculitis with indomethacin. Acta Dermatol (Kyoto) 1985; 80: 9–13Google Scholar
  27. 27.
    Hatta N, Kaeta H, Kodo I. A case of eosinophilic pustular folliculitis treated with indomethacin. Rinsho Derma (Tokyo) 1988; 30: 492–3Google Scholar
  28. 28.
    Kato H. Eosinophilic pustular folliculitis treated with indomethacin. Dermatologica 1989; 179: 217–23PubMedCrossRefGoogle Scholar
  29. 29.
    Nishimura M. Eosinophilic pustular folliculitis effectively controlled with topical indomethacin. Int J Dermatol 1989; 28: 206PubMedCrossRefGoogle Scholar
  30. 30.
    Lee ML, Tham SN, Ng SK. Eosinophilic pustular folliculitis (Ofuji’s disease) with response to indomethacin. Dermatology 1993; 186: 210–2PubMedCrossRefGoogle Scholar
  31. 31.
    Porneuf M, Guillot B, Barneon G, et al. Eosinophilic pustular folliculitis responding to UVB therapy. J Am Acad Dermatol 1993; 29: 259–60PubMedCrossRefGoogle Scholar
  32. 32.
    Misago N, Narisawa Y, Matsubara S, et al. HIV-associated eosinophilic pustular folliculitis: successful treatment of a Japanese patient with UVB phototherapy. J Dermatol 1998; 25: 178–84PubMedGoogle Scholar
  33. 33.
    Steffen C. Eosinophilic pustular folliculitis (Ofuji’s disease) with response to dapsone therapy. Arch Dermatol 1985; 121: 921–3PubMedCrossRefGoogle Scholar
  34. 34.
    Malanin G, Helander I. Eosinophilic pustular folliculitis (Ofuji’s disease): response to dapsone but not to isotretinoin therapy [letter]. J Am Acad Dermatol 1989; 20: 1121PubMedCrossRefGoogle Scholar
  35. 35.
    Berbis P, Jancovici E, Lebreuil G, et al. Eosinophilic pustular folliculitis (Ofuji’s disease): efficacy of isotretinoin. Dermatologica 1989; 179: 214–6PubMedCrossRefGoogle Scholar
  36. 36.
    Otley CC, Avram MR, Johnson RA. Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis: results of an open, pilot trial. Arch Dermatol 1995; 131: 1047–50PubMedCrossRefGoogle Scholar
  37. 37.
    Berger TG, Heon VMS, King C, et al. Itracanazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermotol 1995; 131: 358–60CrossRefGoogle Scholar
  38. 38.
    Smith KJ, Skelton CDR, Yeager J, et al. Metronidazole for eosinophilic pustular folliculitis in human immunodeficiency virus type 1-positive patients. Arch Dermatol 1995; 131: 1089–91PubMedCrossRefGoogle Scholar
  39. 39.
    Inaoka M, Hayakawa J, Shiohra T. HIV seronegative eosinophilic pustular folliculitis successfully treated with metronidazole. J Am Acad Dermatol 2002; 46: S153–5CrossRefGoogle Scholar
  40. 40.
    Harris DW, Ostlere L, Buckley C, et al. Eosinophilic pustular folliculitis in an HIV-positive man: response to cetirizine. Br J Dermatol 1992; 126: 392–4PubMedCrossRefGoogle Scholar
  41. 41.
    Blauvelt A, Plott RT, Spooner K, et al. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. Arch Dermatol 1995; 131: 360–1PubMedCrossRefGoogle Scholar
  42. 42.
    Taniguchi S, Tsurata D, Hamada T. Eosinophilic pustular folliculitis responding to cyclosporin. Br J Dermatol 1994; 131: 736–8PubMedCrossRefGoogle Scholar
  43. 43.
    Dale S, Shaw J. Eosinophilic pustular folliculitis [case report]. Lancet 2000; 356 (9237): 1235PubMedCrossRefGoogle Scholar
  44. 44.
    Laube S, George SA. Adverse effects with PUVA and UVB phototherapy. J Dermatolog Treat 2001; 12 (2): 101–5PubMedCrossRefGoogle Scholar
  45. 45.
    Blachley JD, Blankenship DM, Menter A, et al. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis 1985; 5 (5): 237–41PubMedGoogle Scholar
  46. 46.
    Buchness MR, Lim HW, Hatcher VA, et al. Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome: treatment with ultraviolet B phototherapy. N Engl J Med 1988; 318: 1183–6PubMedCrossRefGoogle Scholar
  47. 47.
    Breuer-McHam J, Marshall G, Adu-Oppong A, et al. Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. J Am Acad Dermatol 1999; 40: 48–60PubMedCrossRefGoogle Scholar
  48. 48.
    Calzavara-Pinton PG, Gavazzoni R, Carlino A, et al. Eosinophilic pustular folliculitis: description of a clinical case treated with PUVA therapy. G Ital Dermatol Venereol 1990; 125: 49–52PubMedGoogle Scholar
  49. 49.
    Breit R, Rocken M. A classical form of eosinophilic pustular folliculitis: successful therapy with PUVA. Hautarzt 1991; 42: 247–50PubMedGoogle Scholar
  50. 50.
    Wolff K. Side-effects of psoralen photochemotherapy (PUVA). Br J Dermatol 1990; 122 Suppl. 36: 117–25PubMedCrossRefGoogle Scholar
  51. 51.
    Stern RS. Ocular lens findings in patients treated with PUVA: Photochemotherapy Follow-Up-Study. J Invest Dermatol 1994; 103 (4): 534–8PubMedCrossRefGoogle Scholar
  52. 52.
    Larralde M, Morales S, Santos Munoz A, et al. Eosinophilic pustular folliculitis in infancy: report of two new cases. Pediatr Dermatol 1999; 16: 118–20PubMedCrossRefGoogle Scholar
  53. 53.
    Kostler E, Gossrau G, Kuster P, et al. Sterile eosinophilic pustulosis (Ofuji): a rare entity in Europe. Hautarzt 1995; 4: 643–6CrossRefGoogle Scholar
  54. 54.
    Taieb A, Bassan-Andrieu L, Maleville J. Eosinophilic pustulosis of the scalp in childhood. J Am Acad Dermatol 1992; 27: 55–60PubMedCrossRefGoogle Scholar
  55. 55.
    Leung AK, Barber KA. Managing childhood atopic dermatitis. Adv Ther 2003; 20 (3): 129–37PubMedCrossRefGoogle Scholar
  56. 56.
    Wolverton SE. Systemic cortocosteroids. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia (PA): W.B. Saunders, 2001: 109–46Google Scholar
  57. 57.
    Mizukawa Y, Shiohara T. Eosinophilic pustular folliculitis induced after prolonged treatment with systemic corticosteroids in a patient with pustulosis palmoplantaris. Acta Derm Venereol 1998; 78: 221–2PubMedCrossRefGoogle Scholar
  58. 58.
    Rattna-Apiromyakij N, Kullavanijaya P. Eosinophilic pustular folliculitis: report of seven cases in Thailand. J Dermatol 2000; 27: 195–203Google Scholar
  59. 59.
    Ishiguro N, Shishido E, Okamoto R, et al. Ofuji’s disease: a report on 20 patients with clinical and histopathologic analysis. J Am Acad Dermatol 2002; 46: 827–33PubMedCrossRefGoogle Scholar
  60. 60.
    Tang MB, Tan E, Chua SH. Eosinophilic pustular folliculitis (Ofuji’s disease) in Singapore: a review of 23 adult cases. Australas J Dermatol 2003; 44: 44–7PubMedCrossRefGoogle Scholar
  61. 61.
    Nishijima S, Sugiyama T, Nakagawa M, et al. Two cases of eosinophilic pustular folliculitis treated by acemetacin. J Dermatol 1994; 21: 779–82PubMedGoogle Scholar
  62. 62.
    Teraki Y, Imanishi K, Shiohara T. Ofuji’s disease and cytokines: remission of eosinophilic pustular folliculitis associated with increased serum concentrations of interferon gamma. Dermatology 1996; 192: 16–8PubMedCrossRefGoogle Scholar
  63. 63.
    Hall RP. Dapsone. In: Wolverton S, editor. Comprehensive dermatologic drug therapy. Philadelphia (PA): W.B. Saunders, 2001Google Scholar
  64. 64.
    Tanigaki T, Kanda R. Two cases of eosinophilic pustular folliculitis treated with minocycline chloride. Rinsho Derma (Tokyo) 1984; 26: 1129–33Google Scholar
  65. 65.
    Shibue K, Shimizu A, Koga T, et al. Three cases of eosinophilic pustular folliculitis. Nishinihon J Dermatol (Fukuoka) 1997; 59: 558–61CrossRefGoogle Scholar
  66. 66.
    Downs AM, Lear JT, Oxley JD, et al. AIDS associated eosinophilic folliculitis which responded to both high dose co-trimoxazole and low dose isotretinoin. Sex Transm Infect 1998; 74: 229–30PubMedGoogle Scholar
  67. 67.
    Komiya N, Tamaoki K. Therapeutic effects of macrolides on patients with psoriasis vulgaris, pigmentary prurigo, or eosinophilic pustule folliculitis. Jpn J Antibiot 2001; 54 Suppl. A: 100–2PubMedGoogle Scholar
  68. 68.
    Rasmussen JE. Antiparasitic Agents. In: Wolverton SE editor. Comprehensive dermatologic drug therapy. Philadelphia (PA): W.B. Saunders, 2001: 537–46Google Scholar
  69. 69.
    Luelmo Aguilar J, Saez Artacho A. Eosinophilic pustular folliculitis in childhood. An Esp Pediatr 2001; 55: 154–8PubMedGoogle Scholar
  70. 70.
    Rogers M. Successful treatment of eosinophilic pustulosis with oral cimetidine [letter]. Pediatr Dermatol 1999; 16: 335–6PubMedCrossRefGoogle Scholar
  71. 71.
    Gupta AK. Systemic antifungal agents. In: Wolverton SE, editor. Comprehensive drug therapy. Philadelphia (PA): W.B. Saunders, 2001: 55–84Google Scholar
  72. 72.
    Nguyen HEQ, Wolverton SE. Systemic retinoids. In: Wolverton SE, editor. Comprehensive drug therapy. Philadelphia (PA): W.B. Saunders, 2001: 269–310Google Scholar
  73. 73.
    Blume-Peytavi U, Chen W, Djemadji N, et al. Eosinophilic pustular folliculitis (Ofuji’s disease). J Am Acad Dermatol 1997; 37: 259–62PubMedCrossRefGoogle Scholar
  74. 74.
    Dubost-Brama A, Delaporte E, Catteau B, et al. Ofuji’s eosinophilic pustular folliculitis: efficacy of acitretin. Ann Dermatol Venereol 1997; 124: 540–3PubMedGoogle Scholar
  75. 75.
    Koo JYM, Lee CS, Maloney JE. Cyclosporin and related drugs. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia (PA): W.B. Saunders, 2001: 205–29Google Scholar
  76. 76.
    Mohr C, Schutte B, Hidebrand A, et al. Eosinophilic pustular folliculitis: successful treatment with interferon-alpha. Dermatology 1995; 191: 257–9PubMedCrossRefGoogle Scholar
  77. 77.
    Fushimi M, Tokura Y, Sachi Y, et al. Eosinophilic pustular folliculitis effectively treated with recombinant interferon-gamma: suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells. Br J Dermatol 1996; 134: 766–72PubMedCrossRefGoogle Scholar
  78. 78.
    Ota T, Hata Y, Tanikawa A, et al. Eosinophic pustular folliculitis: indomethacin as first choice treatment. Clin Exp Dermatol 2001; 26: 179–81PubMedCrossRefGoogle Scholar
  79. 79.
    Meissner K, Kimmig W, Nasemann T. Eosinophilic pustular folliculitis (Ofuji’s disease). Ann Dermatol Venereol 1988; 115: 1207–9PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Elliot Ellis
    • 1
  • Noah Scheinfeld
    • 1
  1. 1.University of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations